Mark Leiser

An investigational vaccine that targets common KRAS mutations induced durable immune responses among individuals at high risk for pancreatic cancer, results of a phase 1 clinical trial showed.Eighteen of 20 participants achieved KRAS-specific T-cell responses. Several individuals had either complete radiographic resolution or regression of pancreatic cysts, and none developed pancreatic cancer by

A highly sensitive blood test can detect signs of pancreatic cancer that standard methods often miss, according to results of a prospective cohort study.Digital droplet polymerase chain reaction (ddPCR) analysis performed upon diagnosis of localized disease detected KRAS-mutant circulating tumor DNA (ctDNA) nearly four times more often than more widely used next-generation sequencing, with

Subcutaneous amivantamab induced rapid and durable responses among patients with HPV-unrelated recurrent or metastatic head and neck cancer, according to study results.Nearly half of patients responded to therapy and more than three-quarters experienced shrinkage of target lesions, findings presented at ASCO Annual Meeting and published simultaneously in Journal of Clinical Oncology showed.

Persistent disparities in preventive cancer care exist among sexual orientation and gender identity minority individuals in the United States, according to results of a cross-sectional analysis.The findings — which revealed particularly concerning gaps related to breast cancer and cervical cancer screening — highlight the need for targeted interventions at the health system, policy

Gaps in cancer mortality based on race or ethnicity continue to narrow overall, but several specific populations still exhibit higher risk for developing or dying of the disease, according to a new report.Outcomes also continue to be worse among residents of rural regions, individuals who live in counties with persistent poverty, and sexual and gender minorities, the AACR Cancer Disparities

The eagerly awaited full dataset from the most pivotal pancreatic cancer study in decades didn’t just live up to expectations.It far exceeded them.

Persistent and prolonged drug shortages across the country are affecting delivery of care across well over 100 therapeutic areas, according to a new report.Shortages are lasting longer than ever, with the average duration now exceeding 5 years, the analysis from United States Pharmacopeia (USP) showed.

CHICAGO — Adding an immunotherapy-based regimen to standard treatment may improve outcomes for some patients with liver cancer who are not candidates for surgery, according to results of the randomized phase 3 EMERALD-3 study.Using STRIDE — single-agent tremelimumab (Imjudo, AstraZeneca) and regular-interval durvalumab (Imfinzi, AstraZeneca) — with transarterial

CHICAGO — The eagerly awaited full dataset from arguably the most pivotal pancreatic cancer trial in decades is now public.Based on the buzz it created among ASCO Annual Meeting attendees, the benefits observed with daraxonrasib among pretreated individuals with metastatic disease exceeded already-lofty expectations.

CHICAGO — The first randomized trial to evaluate whether a multicancer early detection test using a blood sample could result in diagnosis at earlier stages yielded mixed results.The NHS-Galleri trial did not meet its primary endpoint, failing to show a reduction in combined stage III/stage IV diagnoses of 12 prespecified cancer types.